Abigail Beaney

Manchester

Pharmaceutical Reporter at Clinical Trials Arena

Pharmaceutical Reporter @trialsarena 📰

Articles

GLP-1RAs show anti-cancer benefits beyond weight loss

3 days ago | yahoo.com | Abigail Beaney

A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss. The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine, investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide).
GLP-1RAs show anti-cancer benefits beyond weight loss

3 days ago | clinicaltrialsarena.com | Abigail Beaney

A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss. The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine, investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide).
Novo Nordisk’s Sogroya matches Norditropin in children’s growth disorders

3 days ago | clinicaltrialsarena.com | Abigail Beaney

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth disorders in a Phase III trial. The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for gestational age (SGA), with Noonan syndrome (NS), or with idiopathic short stature (ISS)in the Phase III REAL8 basket study (NCT05330325).
Vir’s hepatitis B combo falls short in Phase II trial

4 days ago | clinicaltrialsarena.com | Abigail Beaney

Vir Biotechnology’s ‘functional cure’ combination therapy has failed to meet the efficacy endpoints in a Phase II trial in hepatitis B.
Sanofi exec tells biotechs not to scrimp on clinical trial design

1 week ago | finance.yahoo.com | Abigail Beaney

At a time when the biotech sector has been struggling with a lack of investment, some companies have had to make decisions to change trial designs, whether that be reducing the number of patients or changing the observation times.
Dr. Falk Pharma’s PSC drug achieves endpoints in Phase III trial

1 week ago | clinicaltrialsarena.com | Abigail Beaney

Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing cholangitis (PSC). In the pivotal, Phase III NUC-5 trial, (NCT03872921), NCA showed statistical superiority over placebo in achieving the combined primary endpoints of partial normalisation of blood levels of a liver enzyme linked to PSC (alkaline phosphatase) and no progression of disease stage on histology.
European biotechs must understand US culture while seeking funding

1 week ago | pharmaceutical-technology.com | Abigail Beaney

At a time when investment has been low in biotech, establishing and maintaining good relationships with investors is vital. If European companies are looking to the US for investment, they must understand and accept US culture. Credit: Shutterstock/Melnikov Dmitriy. At a time when the US is becoming more self-focused, European biotechs must understand and appreciate US culture when seeking funding, an expert panel has said.
Expediting parallel drug approval pathways is challenging, but rewarding

1 week ago | pharmaceutical-technology.com | Abigail Beaney

A panel at Swiss Biotech Day 2025 discussed three global parallel drug approval pathways. The panel discussed Project Orbis, ACCESS, and the MAGHP approval pathways, which allow parallel submissions to global agencies. Image credit: GlobalData / Abigail Beaney. Global agencies have collaborated to create parallel regulatory approval solutions to help get drugs to patients more quickly.
Swiss biotech sector’s R&D investment grew in 2024 despite global trends

1 week ago | clinicaltrialsarena.com | Abigail Beaney

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles. While many countries have seen a decline in investment in recent years, according to the Swiss Biotech Report 2025, investment into R&D in Switzerland reached SFr2.6bn ($3.16bn) in 2024, with private company investment accounting for SFr1.4bn of that. Apart from R&D investment, companies in Switzerland raised SFr2.5bn in funds in 2024, a 22% increase on 2023.
AstraZeneca’s triple-combo triumphs in two Phase III asthma trials

2 weeks ago | clinicaltrialsarena.com | Abigail Beaney

AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the primary endpoints in two Phase III asthma trials.